Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer

Oncologist

Volumn 18, Issue 3, 2013, Pages 281-287

  Lee, Michael S ^a,d   Mamon, Harvey J ^a,d   Hong, Theodore S ^b,d   Choi, Noah C ^b,d   Fidias, Panagiotis M ^b,d   Kwak, Eunice L ^b,d   Meyerhardt, Jeffrey A ^c,d   Ryan, David P ^b,d   Bueno, Raphael ^a,d   Donahue, Dean M ^b,d   Jaklitsch, Michael T ^a,d   Lanuti, Michael ^b,d   Rattner, David W ^b,d   Fuchs, Charles S ^c,d   Enzinger, Peter C ^c,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cetuximab; Chemoradiation; EGFR; Esophageal cancer

Indexed keywords

CETUXIMAB; CISPLATIN; IRINOTECAN;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER STAGING; CHYLOTHORAX; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONSTIPATION; DEATH; DEHYDRATION; DESQUAMATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; ESOPHAGITIS; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART INFARCTION; HEMATOLOGIC DISEASE; HUMAN; HYPOMAGNESEMIA; HYPOTENSION; INFECTION; MALE; MUCOSA INFLAMMATION; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; ODYNOPHAGIA; OTOTOXICITY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIATION DOSE; RASH; RESPIRATORY FAILURE; SKIN TOXICITY; SMALL INTESTINE OBSTRUCTION; THROMBOCYTE COUNT; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMORADIOTHERAPY, ADJUVANT; CISPLATIN; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PREOPERATIVE CARE; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; YOUNG ADULT;

EID: 84875434377     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0208     Document Type: Article

References (22)

1. Gebski V, Burmeister B, Smithers BM et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet Oncol 2007;8:226-234.
2. Van der Gaast A, van Hagen P, Hulshof M et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study. J Clin Oncol 2010;28(suppl 15):abstract 4004.
3. Ilson DH, Saltz L, Enzinger P et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 1999;17:3270-3275.
4. Ilson DH, Bains M, Kelsen DP et al. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol 2003;21:2926-2932.
5. Knox JJ, Wong R, Visbal AL et al. Phase 2 trial of of preoperative irinotecan plus cisplatin and confor radiotherapy, followed by surgery for esophageal cancer. Cancer 2010;116:4023-4032.
6. Enzinger PC, Mamon H, Choi N et al. Phase II cisplatin, irinotecan, celecoxib and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer. Presented at the 2004 Gastrointestinal Cancers Symposium; January 22-24, 2004; San Francisco, CA
7. Cronin J, McAdam E, Danikas A et al. Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett's esophagus (BE). Am J Gastroenterol 2011;106:46-56.
8. Wang KL, Wu TT, Choi IS et al. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: Association with poor outcome. Cancer 2007;109:658-667.
9. Itakura Y, Sasano H, Shiga C et al. Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 1994;74:795-804.
10. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-1127.
11. Tew WP, Minsky B, Bains M et al. Phase II trial of preoperative combined modality therapy for esophageal carcinoma: Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy. J Clin Oncol 2005;23(suppl 16):abstract 4017.
12. Kleinberg L, Powell ME, Forastiere A et al. E1201: An Eastern Cooperative Oncology Group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/RT or irinotecan/ isplatin/RT in endoscopy with ultrasound (EUS) staged adenocarcinoma of the esophagus. J Clin Oncol 2007;25(suppl 18):abstract 4533.
13. Tomblyn MB, Goldman BH, Thomas CR Jr et al. Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: A phase-II study of the SWOG (S0414). J Thorac Oncol 2012;7: 906-912.
14. Lledo G, Michel P, Dahan L et al. Chemoradiation with FOLFOX plus cetuximab in locally advanced cardia or esophageal cancer: Final results of a GERCOR phase II trial (ERaFOX). J Clin Oncol 2011; 29(suppl 4):abstract 8.
15. Kleinberg LR, Catalano PJ, Gibson MK et al. ECOG 2205: A phase II study to measure response rate and toxicity of neo-adjuvant chemoradiotherapy (CRT) (IMRT permitted) with oxaliplatin (O) and infusional 5-fluorouracil (5FU) plus cetuximab (C225) in patients with operable adenocarcinoma of the esophagus: High risk of post-op adult respiratory distress syndrome (ARDS). Int J Radiat Oncol Biol Phys 2010;78:S72.
16. Wang SL, Liao Z, Vaporciyan AA et al. Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 2006;64:692-699.
17. Safran H, Suntharalingam M, Dipetrillo T et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: Assessment of toxicity. Int J Radiat Oncol Biol Phys 2008;70:391-395.
18. Ruhstaller T, Pless M, Dietrich D et al. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: A prospective, multicenter phase IB/II trial (SAKK 75/06). J Clin Oncol 2011;29:626-631.
19. Kleinberg L, Powell ME, Forastiere AA et al. Survival outcome of E1201: An Eastern Cooperative Oncology Group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/radiotherapy (RT) or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged esophageal adenocarcinoma. J Clin Oncol 2008;26(suppl 15): abstract 4532.
20. Waddell T, Chau I, Barbachano Y et al. A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3). J Clin Oncol 2012;30(suppl 15):abstract LBA4000.
21. Lennerz JK, Kwak EL, Ackerman A et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011;29:4803-4810.
22. Kwak EL, Jankowski J, Thayer SP et al. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 2006;12:4283-4287